ADMA Biologics prelim Q4 revenue ~$48-50M (+85% YoY); launches public stock offering

ADMA BIOLOGICS, INC.

Preliminary Q4 2022 revenue $48-50M, up >85% YoY from $26.4M; full-year revenue $152-154M.
Launches underwritten public offering of common stock; 30-day option for additional 15% of shares.
Strategic review continues; received non-binding offers but board determined insufficient value.
Expects positive cash flow from operations by Q1 2024; may require additional capital.
Proceeds to accelerate commercialization, production, and plasma center buildout.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ADMA BIOLOGICS, INC. reported year-ended December 31, 2022 results: revenue between $152 million and $154 million.

Period: year-ended December 31, 2022
Revenue: between $152 million and $154 million
Result: preliminary results

Exact text from the filing

ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ADMA BIOLOGICS, INC. reported quarter-ended December 31, 2022 results: revenue between $48 million and $50 million.

Period: quarter-ended December 31, 2022
Revenue: between $48 million and $50 million
Result: preliminary results

Exact text from the filing

ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-22-044592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.